Condition deep-dive · 6 min read

Hyperthyroidism / Graves' disease — supplement adjunct (and what to AVOID)

Updated 2026-05-16 · Reviewed by SupplementScore editors · No sponsorships

Hyperthyroidism — most commonly autoimmune Graves' disease — is the inverse problem to hypothyroidism, and the supplement implications are inverted. The treatments that work are antithyroid drugs (methimazole, carbimazole), radioactive iodine ablation, and thyroidectomy. The supplement layer in hyperthyroidism is primarily about what to AVOID (iodine, kelp, ashwagandha, certain thyroid "supports") and a small set of evidence-supported adjuncts (selenium for mild Graves' orbitopathy, L-carnitine for fatigue and peripheral hyperthyroid symptoms). The risk of getting this wrong is meaningful: iodine in hyperthyroidism can trigger or worsen thyrotoxicosis.

Read this first. Suspected or untreated hyperthyroidism is a medical condition, not a supplement target — it requires endocrinology evaluation for TSH, free T4, free T3, TSI/TRAb antibodies, and management decisions (methimazole vs RAI vs surgery). Thyroid storm is a medical emergency. Pregnancy with Graves' requires specialist care. New atrial fibrillation, unexplained weight loss with tremor, or proptosis with diplopia warrant prompt evaluation. This page is for adjunctive options alongside conventional care, not as a substitute.

What has trial evidence as adjunct

Tier 2 evidence · Mild Graves' orbitopathy

Selenium (selenomethionine)

100 mcg b.i.d. (200 mcg/day) for 6 months

Marcocci 2011 (EUGOGO trial, n=159, Graves' orbitopathy of mild severity) showed 200 mcg/day selenomethionine for 6 months produced significant improvements in quality of life and ophthalmic outcomes versus placebo. This is the strongest supplement evidence in the hyperthyroidism / Graves' space. Test selenium status if possible; the Italian population studied had moderate selenium adequacy. Stop at 6 months; avoid chronic high-dose selenium (toxicity above 400 mcg/day chronically).

Tier 2 evidence · Hyperthyroid symptoms (fatigue, weakness)

L-Carnitine

2–4 g/day in divided doses

Benvenga 2001 and follow-on trials show L-carnitine reduces symptoms of hyperthyroidism (fatigue, weakness, tremor, palpitations) when added to antithyroid therapy. Mechanism: carnitine inhibits cellular thyroid-hormone uptake into nuclei. Reasonable adjunct during the early treatment phase before antithyroid drugs take full effect. Discuss with endocrinologist before starting.

Tier 2 evidence · Bone protection during hyperthyroid phase

Vitamin D3 + Calcium

Vitamin D3 2000 IU/day to 25-OH-D target of 30–50 ng/mL + calcium 1000–1200 mg/day total intake (preferentially from diet)

Hyperthyroidism accelerates bone turnover and can produce significant bone loss, particularly in postmenopausal women. Maintaining adequate vitamin D and calcium status during the hyperthyroid phase and recovery period supports bone preservation. Test 25-OH-D first; supplement to target. Calcium primarily from diet; supplement to fill gaps only.

Tier 3 evidence · Antioxidant adjunct

Vitamin C + Vitamin E (mixed tocopherols)

Vitamin C 500 mg/day; Vitamin E 400 IU/day mixed tocopherols

Hyperthyroid metabolic state generates increased oxidative stress; small trials show modest reductions in oxidative-stress biomarkers with antioxidant supplementation. Effect on clinical outcomes is unclear. Vitamin E high-dose has independent cardiovascular concerns; use mixed tocopherols and reasonable doses.

What to AVOID — much more important than what to take

Iodine supplements (any form: KI, kelp, bladderwrack, "thyroid support" iodine, Lugol's solution) — iodine load in hyperthyroidism can paradoxically worsen thyrotoxicosis (Jod-Basedow phenomenon) or precipitate thyroid storm in severe cases.
Kelp and seaweed supplements — frequently very high iodine, with significant variability; avoid.
Iodised salt — typical dietary intake is fine in treated hyperthyroidism; the concern is concentrated supplemental sources.
Tyrosine — substrate for thyroid hormone synthesis; theoretical risk of fuelling hormone production.
Ashwagandha — generally promoted as adaptogenic but has evidence of increasing thyroid hormone output (Sharma 2018 in subclinical hypothyroid showed T4 increase). Avoid in hyperthyroidism.
"Thyroid glandulars" / desiccated bovine thyroid — exogenous thyroid hormone source; will worsen hyperthyroidism.
Selenium chronic high-dose (above 400 mcg/day) — selenosis (hair loss, nail brittleness, GI upset, neurological effects); the EUGOGO Graves' protocol uses 200 mcg for 6 months only.
"Adrenal support" formulas containing licorice (glycyrrhiza) — licorice has mineralocorticoid effects; can worsen hyperthyroid-related cardiovascular symptoms.
High-dose biotin (5–10 mg) — interferes with TSH and free T4 immunoassays, producing falsely low TSH and falsely high free T4 — can mimic or mask hyperthyroidism on labs. Stop 48–72 hours before any thyroid testing.
Stimulant pre-workouts containing caffeine/synephrine/yohimbine — hyperadrenergic state worsens tremor, tachycardia, anxiety in untreated or partially treated hyperthyroidism.

The behavioural and clinical foundation

Aside from medical management, several environmental and behavioural levers matter:

Smoking cessation — smoking is the single strongest modifiable risk factor for Graves' orbitopathy and worsens its course; cessation is critical.
Sleep prioritisation — hyperthyroidism disrupts sleep; protect 7–9 hours; treat insomnia.
Stress management — stress can be a trigger and exacerbating factor; CBT, mindfulness, and adequate recovery are reasonable supports.
Eye care for Graves' orbitopathy — preservative-free artificial tears, sunglasses for photophobia, prism correction for diplopia, head-of-bed elevation for nighttime periorbital edema.
Bone health monitoring — DXA scan in postmenopausal women with hyperthyroidism, particularly if longstanding before treatment.
Cardiovascular monitoring — atrial fibrillation risk; rate control and anticoagulation decisions per cardiology.

What to track

TSH, free T4, free T3 at intervals set by your endocrinologist (typically every 4–6 weeks during dose titration, then 3–6 months on stable therapy). TSI/TRAb antibody levels track Graves' activity. For orbitopathy: the Clinical Activity Score (CAS) and Quality of Life (GO-QOL) questionnaires. Symptom diary (palpitations, tremor, sleep, weight, heat tolerance) is useful for medication-titration discussions. Stop biotin and high-dose B-vitamin complexes ≥48 hours before any thyroid panel.

Practical quick-start. Avoid the high-risk supplements (iodine in any form, kelp, ashwagandha, thyroid glandulars, high-dose biotin around labs). Smoking cessation is the most powerful single modifiable input, especially with orbitopathy. For mild Graves' orbitopathy: selenium 100 mcg b.i.d. for 6 months. For hyperthyroid symptom load: L-carnitine 2–4 g/day adjunct to antithyroid therapy, after endocrinologist discussion. Maintain vitamin D and calcium status. The supplement layer is small and constrained — the medical layer is the actual treatment.

Educational reference, not medical advice. Hyperthyroidism requires endocrinology care. Discuss any supplement change — especially iodine, ashwagandha, biotin, or selenium — with your prescriber.